The role and medical prospects of long non-coding RNAs in cardiovascular disease

Heart Fail Rev. 2023 Nov;28(6):1437-1453. doi: 10.1007/s10741-023-10342-1. Epub 2023 Oct 5.

Abstract

Cardiovascular disease (CVD) has reached epidemic proportions and is a leading cause of death worldwide. One of the long-standing goals of scientists is to repair heart tissue damaged by various forms of CVD such as cardiac hypertrophy, dilated cardiomyopathy, myocardial infarction, heart fibrosis, and genetic and developmental heart defects such as heart valve deformities. Damaged or defective heart tissue has limited regenerative capacity and results in a loss of functioning myocardium. Advances in transcriptomic profiling technology have revealed that long noncoding RNA (lncRNA) is transcribed from what was once considered "junk DNA." It has since been discovered that lncRNAs play a critical role in the pathogenesis of various CVDs and in myocardial regeneration. This review will explore how lncRNAs impact various forms of CVD as well as those involved in cardiomyocyte regeneration. Further, we discuss the potential of lncRNAs as a therapeutic modality for treating CVD.

Keywords: Cardiovascular disease; RNA-based therapy; Therapeutic targets; lncRNA.

Publication types

  • Review

MeSH terms

  • Cardiomegaly / genetics
  • Cardiovascular Diseases* / genetics
  • Humans
  • Myocardium / pathology
  • Myocytes, Cardiac / pathology
  • RNA, Long Noncoding* / genetics

Substances

  • RNA, Long Noncoding